The constitutive activation of signaling pathways downstream of EGFR drive the growth and progression of CRC and provide an escape mechanism that allows tumors to overcome the pharmacological blockade induced by anti-EGFR mAb [37]. The gene discussed is EGFR; the disease is colorectal carcinoma.